Five-year, 18-site control system upgrade program is put in place to increase asset utilization, lower obsolescence risk, and ...

Joining us today will be Kevin Clark, Aptiv's Chair and Chief Executive Officer; and Varun Laroyia, Executive Vice President and Chief Financial Officer. Kevin will provide a strategic update on the ...

In a recent analysis conducted by Oil Change International, researchers determined that fossil fuel firms receive around $31 ...

Shell plc ( SHEL) Q3 2025 Earnings Call October 30, 2025 10:30 AM EDT Welcome to Shell's Third Quarter 2025 Financial Results Announcement. Shell's CFO, Sinead Gorman, will present the results, then ...

This article first appeared on GuruFocus. Standard Chartered (SCBFY) just delivered the kind of quarter investors pay ...

Q3 2025 Management View Chris Stavros, President, CEO & Chairman, highlighted Magnolia's "record quarterly total production ...

Merck & Co. shaved the top end of its 2025 revenue guidance and failed to produce any standout sales beats for its medicines ...

As European markets experience a notable upswing, with the STOXX Europe 600 Index climbing 1.68% and major indices across Germany, Italy, France, and the UK showing positive momentum, investors are ...

Patients with stroke who receive intra-arterial thrombolysis after thrombectomy are more likely to achieve superior 90-day ...

Hays' stock price target has seen subtle adjustments, as analysts weigh both optimistic and cautious signals about the company’s market prospects. The fair value assessment remains steady, while a ...

Imagion Biosystems, Singular Health and Audeara were among ASX health companies reporting quarterly results this week.

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.